Protagenic chair buys 2,700 shares at $0.35

Protagenic Therapeutics, Inc. (PTIX) reported that director and executive chair Armen Garo H purchased 2,700 shares of common stock on 2026-08-19 in an open-market or private transaction at $0.35 per share.

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. (PTIX) reported that director and executive chair Armen Garo H purchased 2,700 shares of common stock on 2026-08-19 in an open-market or private transaction at $0.35 per share. Following this purchase, he directly owns 36,899 common shares. The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 2,700 shares

Net Buy 1 txn

Insider ARMEN GARO H

Role EXEC. CHAIR & PRINCIPAL OFF

Bought 2,700 shs ($945.00)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	2,700	$0.35	$945.00

Holdings After Transaction: COMMON STOCK — 36,899 shares (Direct)

Key Figures

Shares purchased: 2,700 shares Purchase price: $0.35 per share Shares owned after transaction: 36,899 shares

3 metrics

Shares purchased 2,700 shares Common stock purchased on 2026-08-19 by Armen Garo H

Purchase price $0.35 per share Price for common stock purchase on 2026-08-19

Shares owned after transaction 36,899 shares Direct common stock ownership by Armen Garo H after the purchase

Key Terms

Form 4, open market or private transaction, Rule 10b5-1 trading plan

3 terms

Form 4 regulatory

"Protagenic Therapeutics (PTIX) insider transaction was reported on a Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction financial

"Transaction code description is Purchase in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTIX report for Armen Garo H?

Protagenic Therapeutics (PTIX) reported that Armen Garo H bought 2,700 common shares on 2026-08-19. The shares were acquired in a purchase in open market or private transaction at $0.35 per share, increasing his direct holdings.

How many PTIX shares does Armen Garo H own after the latest Form 4?

After the reported transaction, Armen Garo H directly owns 36,899 PTIX common shares. This reflects the addition of 2,700 shares purchased on 2026-08-19 at $0.35 per share in an open-market or private transaction.

What price did Armen Garo H pay for PTIX shares on 2026-08-19?

He paid $0.35 per share for 2,700 PTIX common shares on 2026-08-19. The filing characterizes the transaction as a purchase in open market or private transaction, and it increased his direct ownership to 36,899 shares.

Was the recent PTIX insider trade under a Rule 10b5-1 trading plan?

The filing indicates the transaction was not affirmed as under a Rule 10b5-1 trading plan. The document-level checkbox for Rule 10b5-1 was marked false, and no footnotes describe this purchase as pursuant to a trading plan.

What role does Armen Garo H hold at Protagenic Therapeutics (PTIX)?

Armen Garo H is reported as a director and officer of Protagenic Therapeutics, with the title EXEC. CHAIR & PRINCIPAL OFF. His recent Form 4 discloses a purchase of 2,700 common shares, bringing direct ownership to 36,899 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 09:24 AM Accepted by SEC EDGAR 08/20/2026 - 09:23 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON, MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagenic Therapeutics, Inc.\new [ PTIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. CHAIR & PRINCIPAL OFF

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	08/19/2026		P		2,700	A	$0.35	36,899	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Garo H. Armen	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)